Drug Trial Radar · NCT06667960
Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
255
Planned (sponsor's estimate)
Start
Oct 23, 2024
Primary completion
Apr 1, 2028
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Salubris Biotherapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
Conditions
- Solid Tumor
Interventions
JK06Drug
Biparatopic anti-5T4 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting Toxicity (DLT)Time frame: First 21 days of treatment.
- Dose-FindingTime frame: From First Patient Dosed to end of Escalation, up to 14 months.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: First treatment through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Screening date through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.
- Objective Response Rate (ORR)Time frame: From date of randomization until the date of first documented progression, assessed up to 104 weeks
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium · Recruiting
Institut Jules Bordet
Brussels, Belgium · Recruiting
UZ Ghent
Ghent, Belgium · Recruiting
CHU UCL Namur - site Godinne
Yvoir, Belgium · Recruiting
NEXT Oncology Barcelona
Barcelona, Spain · Recruiting
START Barcelona
Barcelona, Spain · Recruiting
Vall d Hebron Institute of Oncology VHIO
Barcelona, Spain · Recruiting
CUN Madrid
Madrid, Spain · Recruiting
October 12th Hospital
Madrid, Spain · Recruiting
Next Oncology Madrid
Madrid, Spain · Recruiting
START Madrid
Madrid, Spain · Recruiting
CUN Pamplona
Pamplona, Spain · Recruiting
START Rioja
Rioja, Spain · Recruiting
Instituto de Investigación Sanitaria INCLIVA
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.